Bristol Myers CEO sees mid-decade transition, late decade growth
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Bristol-Myers Squibb tops Q4 expectations, reports strong anemia drug sales
February 2, 2024 7:42 AM ESTShares of Bristol-Myers Squibb (NYSE: BMY) advanced 2.5% in the market pre-open Friday after the pharmaceutical company unveiled better-than-expected earnings and revenue for the fiscal fourth quarter.
Notably, Bristol reported Q4 earnings per share (EPS) of $1.70, ahead of Wall Streets consensus of $1.60. Revenue stood at $11.48 billion in the... More
